Agios Q2 2023: PYRUKYND revenue $6.7M; net loss $83.8M; pipeline advances

AGIOS PHARMACEUTICALS, INC.

2023-Q2 EPS reported -$2.97 revenue$12,321,000

PYRUKYND net revenue $6.7M in Q2, up 20% QoQ; 147 patients completed enrollment forms, 99 on therapy.
Net loss $83.8M vs $91.8M a year ago; cash $946.9M, expected runway into 2026.
Phase 2 mitapivat in sickle cell positive; Phase 3 enrollment to begin Q4 2023.
Completed enrollment in Phase 3 thalassemia studies (ENERGIZE/ENERGIZE-T) and Phase 2a AG-946 in LR-MDS.
Licensed Alnylam siRNA for polycythemia vera; appointed Catherine Owens to board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.65

AGIOS PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $6.7 million, net income $83.8 million.

Period: the second quarter ended June 30, 2023
Revenue: $6.7 million
Net income: $83.8 million
Result: reported results

Exact text from the filing

License Agreement with Alnylam Pharmaceuticals to License Alnylam’s Novel siRNA for the Potential Treatment of Polycythemia Vera – U.S. PYRUKYND ® (mitapivat) Net Revenue of $6.7 Million in Q2; $947 Million of Cash, Cash Equivalents and Marketable Securities as of June 30, 2023 CAMBRIDGE, Mass., August 3, 2023 -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001439222-23-000117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.